Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy

Open access

Abstract

Aims: Glucagon-like peptide-1 receptor agonists are effective treatments for type 2 diabetes, effectively lowering glucose without weight gain and with low risk for hypoglycemia. However, their influence on the retinal neurovascular unit remains unclear. In this study, we analyzed the effects of the GLP-1 RA lixisenatide on diabetic retinopathy. Methods: Vasculo- and neuroprotective effects were assessed in experimental diabetic retinopathy and high glucose-cultivated C. elegans, respectively. In STZ-diabetic Wistar rats, acellular capillaries and pericytes (quantitative retinal morphometry), neuroretinal function (mfERG), macroglia (GFAP western blot) and microglia (immunohistochemistry) quantification, methylglyoxal (LC–MS/MS) and retinal gene expressions (RNA-sequencing) were determined. The antioxidant properties of lixisenatide were tested in C. elegans. Results: Lixisenatide had no effect on glucose metabolism. Lixisenatide preserved the retinal vasculature and neuroretinal function. The macro- and microglial activation was mitigated. Lixisenatide normalized some gene expression changes in diabetic animals to control levels. Ets2 was identified as a regulator of inflammatory genes. In C. elegans, lixisenatide showed the antioxidative property. Conclusions: Our data suggest that lixisenatide has a protective effect on the diabetic retina, most likely due to a combination of neuroprotective, anti-inflammatory and antioxidative effects of lixisenatide on the neurovascular unit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00592-023-02135-7

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Metabolic and biochemical effects of lixisenatide in diabetic rats. a HbA1c (n = 6–13, 1way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001), b blood glucose (● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic, n = 7, 2way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001: significance NC vs. DC and NC vs. DC + Lixi), c body weight (● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic, n = 9–13, 2way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001: significance NC vs. DC and NC vs. DC + Lixi) and d retinal methylglyoxal concentrations (n = 6, 1way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001). All data are expressed as mean ± SD
Fig. 1 Metabolic and biochemical effects of lixisenatide in diabetic rats. a HbA1c (n = 6–13, 1way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001), b blood glucose (● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic, n = 7, 2way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001: significance NC vs. DC and NC vs. DC + Lixi), c body weight (● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic, n = 9–13, 2way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001: significance NC vs. DC and NC vs. DC + Lixi) and d retinal methylglyoxal concentrations (n = 6, 1way ANOVA, Tukey´s multiple comparisons test, ***p < 0.001). All data are expressed as mean ± SDCC BY · PubMed Central
Fig. 2 Effect of lixisenatide on experimental diabetic retinopathy. a Numbers of acellular capillaries and b pericyte numbers in capillary areas were determined by quantitative retinal morphometry of PAS-stained retinal digest preparations. NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD; 1way ANOVA, Tukey´s multiple comparisons test (a) and unpaired t-test (b), * p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2 Effect of lixisenatide on experimental diabetic retinopathy. a Numbers of acellular capillaries and b pericyte numbers in capillary areas were determined by quantitative retinal morphometry of PAS-stained retinal digest preparations. NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD; 1way ANOVA, Tukey´s multiple comparisons test (a) and unpaired t-test (b), * p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 3 Assessment of neuroretinal function of lixisenatide. Multifocal electroretinography measurements of a a-wave amplitude (photoreceptor function) and b b-wave amplitude (inner retinal neurons) at 12 weeks. c OCT of retinal thickness at 6 weeks. ● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 2way ANOVA, Tukey’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001. *NC versus DC, + NC versus DC + Lixi, # DC versus DC + Lixi
Fig. 3 Assessment of neuroretinal function of lixisenatide. Multifocal electroretinography measurements of a a-wave amplitude (photoreceptor function) and b b-wave amplitude (inner retinal neurons) at 12 weeks. c OCT of retinal thickness at 6 weeks. ● NC = non-diabetic; ■ DC = diabetic; ▲ DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 2way ANOVA, Tukey’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001. *NC versus DC, + NC versus DC + Lixi, # DC versus DC + LixiCC BY · PubMed Central
Fig. 4 Quantification of glial activation. a Glial activation was quantified by Western blotting using GFAP (glial fibrillary acidic protein) as a marker (n = 5–6). b Representative blot for GFAP and β-Tubulin as loading control. NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 1way ANOVA, Tukey´s multiple comparisons test, *p < 0.05, ***p < 0.001
Fig. 4 Quantification of glial activation. a Glial activation was quantified by Western blotting using GFAP (glial fibrillary acidic protein) as a marker (n = 5–6). b Representative blot for GFAP and β-Tubulin as loading control. NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 1way ANOVA, Tukey´s multiple comparisons test, *p < 0.05, ***p < 0.001CC BY · PubMed Central
Fig. 5 Quantification of microglial activation. Assessment of microglial activation by quantification of a Iba-1 + and b CD74 + positive cells (n = 3). NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 1way ANOVA, Tukey´s multiple comparisons test, *p < 0.05, **p < 0.01
Fig. 5 Quantification of microglial activation. Assessment of microglial activation by quantification of a Iba-1 + and b CD74 + positive cells (n = 3). NC = non-diabetic; DC = diabetic; DC + Lixi = Lixisenatide-treated diabetic. Data are expressed as mean ± SD, 1way ANOVA, Tukey´s multiple comparisons test, *p < 0.05, **p < 0.01CC BY · PubMed Central
Fig. 6 Volcanoplot of genes detected by RNAseq of retinae (n = 6). a 66 genes show significant levels of regulation between the untreated diabetic animals and the healthy control animals (DC vs. NC). b Lixisenatide normalizes diabetic gene regulation. c The differences between untreated and Lixisenatide-treated diabetic animals are not statistically significant (DC + Lixi vs. DC)
Fig. 6 Volcanoplot of genes detected by RNAseq of retinae (n = 6). a 66 genes show significant levels of regulation between the untreated diabetic animals and the healthy control animals (DC vs. NC). b Lixisenatide normalizes diabetic gene regulation. c The differences between untreated and Lixisenatide-treated diabetic animals are not statistically significant (DC + Lixi vs. DC)CC BY · PubMed Central
Fig. 7 Regulatory network of astrocyte-annotated genes. The genes Ets2, FOS and JUN are phosphorylated via p38/MAPK14 (blue arrows). MAPK14 and JUN lead to the upregulation of NFKB1 (green arrows) (Color figure online)
Fig. 7 Regulatory network of astrocyte-annotated genes. The genes Ets2, FOS and JUN are phosphorylated via p38/MAPK14 (blue arrows). MAPK14 and JUN lead to the upregulation of NFKB1 (green arrows) (Color figure online)CC BY · PubMed Central
Fig. 8 Formation of reactive oxygen species (ROS) in C. elegans. Nematodes were cultured under standard (S) or high glucose (HG) conditions. For additional treatment, lixisenatide was added at concentration of 6 µM, 2 µM, 0.6 µM, 0.2 µM and 0.02 µM to the high glucose condition (HG + Lixi). ROS formation was detected by confocal laser scanning microscopy (CLSM) of ethidium-labeled nematodes at 12 days of age and quantified by calculation of mean pixel values [arbitrary units (AU)/pixel]. Shown are the results of one representative experiment from three independent experiments. a Representative CLMS images of the respective groups. b Summary of quantified ROS formation. Shown are MW ± SD (n = 7–21). Significance against HG condition was calculated using Tukey's multiple comparisons test, ***p < 0.001
Fig. 8 Formation of reactive oxygen species (ROS) in C. elegans. Nematodes were cultured under standard (S) or high glucose (HG) conditions. For additional treatment, lixisenatide was added at concentration of 6 µM, 2 µM, 0.6 µM, 0.2 µM and 0.02 µM to the high glucose condition (HG + Lixi). ROS formation was detected by confocal laser scanning microscopy (CLSM) of ethidium-labeled nematodes at 12 days of age and quantified by calculation of mean pixel values [arbitrary units (AU)/pixel]. Shown are the results of one representative experiment from three independent experiments. a Representative CLMS images of the respective groups. b Summary of quantified ROS formation. Shown are MW ± SD (n = 7–21). Significance against HG condition was calculated using Tukey's multiple comparisons test, ***p < 0.001CC BY · PubMed Central
Fig. 9 Potential mechanism of lixisenatide action. In diabetes, there is an accumulation of MG/AGE, which activates p38/MAPK14 via the RAGE pathway and leads to an increase in NFkB levels. This leads to vasoregression, neuronal dysfunction and inflammation. Since the amount of retinal MG was not affected by lixisenatide, the protective effect of lixisenatide is probably mediated downstream from the MG/AGE-RAGE. Lixisenatide inhibits the expression of Ets2 and thus can inhibit the activation of p38/MAPK14
Fig. 9 Potential mechanism of lixisenatide action. In diabetes, there is an accumulation of MG/AGE, which activates p38/MAPK14 via the RAGE pathway and leads to an increase in NFkB levels. This leads to vasoregression, neuronal dysfunction and inflammation. Since the amount of retinal MG was not affected by lixisenatide, the protective effect of lixisenatide is probably mediated downstream from the MG/AGE-RAGE. Lixisenatide inhibits the expression of Ets2 and thus can inhibit the activation of p38/MAPK14CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Abràmoff MD, Magalhães PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11(7):36–42
  2. Da Silva S et al (2010) Antioxidants in the prevention and treatment of diabetic retinopathy a review. J Diabet Metabol 1:111. https://doi.org/10.4172/2155-6156.100011 · doi:10.4172/2155-6156.100011

Cited by

See all 22

Metadata

Authors
Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P.
Affiliations
  • Heidelberg University (DE)
  • Sanofi (Germany) (DE)
Corresponding author
Oezer, Kuebra
Venue
Acta Diabetologica
Published
2023-07-09
Volume
60
Issue
11
Pages
1551-1565
ISSN
  • 0940-5429 (ISSN-L)
  • 1432-5233
OpenAlex
W4383676238
Cited by
22
References
56
Citations by year
2026: 9 · 2025: 7 · 2024: 6
FWCI
5.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Diabetologica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • GRK 1874/2 DIAMICOM
  • SFB 1118
  • Sanofi-Aventis Deutschland
  • European Foundation for the Study of Diabetes
  • NIH Office of Research Infrastructure Programs
  • Medizinische Fakultät Mannheim der Universität Heidelberg
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
lixisenatide, GLP-1 receptor agonists, diabetic retinopathy, neurovascular unit, retinal neuroprotection, retinal vasculature, pericytes, microglial activation, macroglia, ETS2, inflammation, oxidative stress, antioxidant activity, methylglyoxal, retinal gene expression, streptozotocin-induced diabetes, Caenorhabditis elegans
MeSH terms
Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antioxidants, Chromatography, Liquid, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glucose, Hypoglycemic Agents, Peptides, Caenorhabditis elegans, Rats, Wistar, Rats, Tandem Mass Spectrometry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy. https://app.cochat.ai/papers/10.1007/s00592-023-02135-7
The paper
Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P. (2023). The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy. Acta Diabetologica. https://doi.org/10.1007/s00592-023-02135-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.